Repare Therapeutics Inc. (RPTX) financial statements (2022 and earlier)
Company profile
| Business Address |
7210 FREDERICK-BANTING, SUITE 100 ST-LAURENT, QC H4S 2A1 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 341,866 | 333,710 | ||
| Cash and cash equivalents | 334,427 | 326,184 | ||
| Short-term investments | 7,439 | 7,526 | ||
| Prepaid expense | 6,314 | 6,678 | ||
| Other undisclosed current assets | 3,234 | 6,164 | ||
| Total current assets: | 351,414 | 346,552 | ||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | 7,491 | 4,674 | ||
| Property, plant and equipment | 5,604 | 3,948 | ||
| Restricted cash and investments | 212 | |||
| Deferred income tax assets | 3,620 | 1,412 | ||
| Other noncurrent assets | 586 | 288 | ||
| Total noncurrent assets: | 17,301 | 10,534 | ||
| TOTAL ASSETS: | 368,715 | 357,086 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 8,079 | 5,476 | ||
| Accounts payable | 2,302 | 2,251 | ||
| Accrued liabilities | 387 | 436 | ||
| Employee-related liabilities | 4,867 | 2,771 | ||
| Taxes payable | 523 | 18 | ||
| Deferred revenue | 11,921 | 2,073 | ||
| Other liabilities | 377 | 184 | ||
| Other undisclosed current liabilities | 14,712 | 3,281 | ||
| Total current liabilities: | 35,089 | 11,014 | ||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 5,592 | 3,308 | ||
| Operating lease, liability | 5,592 | 3,308 | ||
| Liabilities, other than long-term debt | 39,613 | 55,934 | ||
| Deferred revenue | 39,613 | 55,934 | ||
| Total noncurrent liabilities: | 45,205 | 59,242 | ||
| Total liabilities: | 80,294 | 70,256 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent | 288,421 | 286,830 | ||
| Common stock | 480,699 | 384,313 | ||
| Additional paid in capital | 17,988 | 5,875 | ||
| Accumulated deficit | (210,266) | (103,358) | ||
| Total stockholders' equity: | 288,421 | 286,830 | ||
| TOTAL LIABILITIES AND EQUITY: | 368,715 | 357,086 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|
| Gross profit: | (1,873) | (890) | |
| Operating expenses | (116,260) | (54,437) | |
| Other undisclosed operating income | 9,473 | 1,025 | |
| Operating loss: | (108,660) | (54,302) | |
| Nonoperating income (expense) | 74 | (440) | |
| Investment income, nonoperating | 259 | 240 | |
| Foreign currency transaction loss, before tax | (144) | (664) | |
| Other nonoperating expense | (41) | (16) | |
| Loss from continuing operations before income taxes: | (108,586) | (54,742) | |
| Income tax benefit | 1,678 | 1,325 | |
| Net loss available to common stockholders, diluted: | (106,908) | (53,417) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|
| Net loss: | (106,908) | (53,417) | |
| Comprehensive loss, net of tax, attributable to parent: | (106,908) | (53,417) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.